Group 1 - Ionis Pharmaceuticals has reported positive results from a pivotal study of its experimental medicine, zilganersen, aimed at treating Alexander disease, a rare neurological disorder [5] - The study demonstrated that a 50 mg dose of zilganersen significantly improved outcomes for patients suffering from Alexander disease [5]